SITC Cancer Immunotherapy CONNECT

Register for Upcoming Advances in Cancer Immunotherapy™ Programs in
Philadelphia, PA & Milwaukee, WI

Join SITC Aug. 4 in Philadelphia, PA and Aug. 12 in Milwaukee, WI for upcoming Advances in Cancer Immunotherapy™ (ACI) programs to learn clinical applications of immunotherapy for disease states with FDA-approved treatments and much more!



Submit Your Research to the 32nd Annual Meeting & Pre-Conference Programs

Submit your research by August 1 to SITC 2017, the premier destination for scientific exchange, education and networking in the cancer immunotherapy field.

Submit Your Abstract TODAY


Begin your free online education today at SITC Cancer Immunotherapy connectED

SITC connectED is the new adaptive learning portal connecting users to online educational activities about cancer immunotherapy with opportunities for continuing education credits. Start with Introduction to Immunology lead by Christian Capitini, MD (University of Wisconsin).

Explore SITC connectED



SITC members who purchase Cancer Immunotherapy Principles and Practice receive a 20 percent discount and free shipping with a promo code.*

member-ribbon-v4.png*Available only when ordering from Demos Medical Publishing. Cannot be combined with any other offers.

Learn More

Non-Small Cell Lung Cancer Immunotherapy: Clinical Management

Complete this FREE online CME/CNE activity to learn more about immunotherapy for non-small cell lung cancer, then engage your patients in discussion today!

*Current as of August 2016

Earn Your Credit


Join the Discussion – Create a SITC Cancer Immunotherapy CONNECT Account

Learn and share information in the new SITC Cancer Immunotherapy CONNECT Open Forum! Follow a few easy steps to create a free SITC CONNECT account, upload a profile photo and join the conversation.


Clinical Advances in Cancer Immunotherapy Online Portal

In partnership with Medscape Oncology, SITC offers a robust online learning portal designed to provide clinical oncologists with free, CME-/CE-certified education in the immunotherapy field.

Learn More


Explore resources and educational opportunities for cancer patients and those who advocate for them.







Track the latest advancements and educational opportunities in cancer immunotherapy and immunology.







Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.






Latest Discussions

  • The European Commission has recently approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this group of patients. In this exclusive interview with Oncology Central, ...

  • Chimeric antigen receptor (CAR) T cell therapy shows effectiveness against hematologic malignancies, particularly, against B-cell acute lymphoblastic leukemia in clinical trials. But is also to be enhanced for solid cancers. CARs can increase tumor specificity ...

    1 person recommends this.
  • I've seen a couple of patients on doses of prednisone as high as 40 BID with complete responses to PD-1/PD-L1 therapy. I'm not aware of robust data that shows steroids reduce efficacy. The largest study on this that I'm aware of found no difference in ...

Follow the SITC Twitter Feed.


Connect with colleagues at these Upcoming Events.


Ignite the Sparkathon

Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.


Learn More


Publications & Resources

Journal for ImmunoTherapy of Cancer

An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.

Learn More


Making Cure a Reality

It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.


Learn More